A Registry for People With T-cell Lymphoma

Status Recruiting

Clinical Trial Summary

The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more about how to improve outcomes for people with T-cell lymphoma.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Adult T-cell Leukemia/Lymphoma
Aggression
Aggressive NK-cell Leukemia
Anaplastic Large Cell Lymphoma, ALK-negative
Anaplastic Large Cell Lymphoma, ALK-Positive
Angioimmunoblastic T-cell Lymphoma
Breast Implant-Associated Anaplastic Large Cell Lymphoma
Enteropathy-associated T-cell Lymphoma
Epstein-Barr Virus Infections
Extranodal NK/T-cell Lymphoma, Nasal Type
Follicular T-Cell Lymphoma
Hepatosplenic T-cell Lymphoma
Leukemia
Leukemia, Prolymphocytic
Leukemia, Prolymphocytic, T-Cell
Leukemia, T-Cell
Leukemia-Lymphoma, Adult T-Cell
Lymphoma
Lymphoma, Extranodal NK-T-Cell
Lymphoma, Large-Cell, Anaplastic
Lymphoma, Non-Hodgkin
Lymphoma, Primary Cutaneous Anaplastic Large Cell
Lymphoma, T-Cell
Lymphoma, T-Cell, Cutaneous
Lymphoma, T-Cell, Peripheral
Lymphoproliferative Disorders
Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma
Mycoses
Mycosis Fungoides
NK-Cell Lymphoma
Nodal Peripheral T-Cell Lymphoma With TFH Phenotype
Panniculitis
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Primary Cutaneous Anaplastic Large Cell Lymphoma
Primary Cutaneous T-cell Lymphoma
Sezary Syndrome
Subcutaneous Panniculitis-Like T-Cell Lymphoma
T-cell Large Granular Lymphocytic Leukemia
T-cell Lymphoma
T-cell Prolymphocytic Leukemia

Clinical Trial Details

NCT number	NCT05978141
Study type	Observational [Patient Registry]
Source	Memorial Sloan Kettering Cancer Center
Contact	Steven Horwitz, MD
Phone	646-608-2680
Email	horwitzs@MSKCC.ORG
Status	Recruiting
Phase
Start date	July 27, 2023
Completion date	July 27, 2030

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02168140` - CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma	Phase 1
Completed	`NCT01427881` - Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies	Phase 2
Completed	`NCT00078858` - Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant	Phase 1/Phase 2
Completed	`NCT00006473` - Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	Phase 2
Completed	`NCT00003196` - Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma	N/A
Terminated	`NCT01678443` - Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies	Phase 1
Terminated	`NCT01408043` - Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma	N/A
Completed	`NCT01466881` - Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma	Phase 2
Completed	`NCT00608361` - Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery	Phase 1
Completed	`NCT00131937` - Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma	Phase 2
Completed	`NCT00098891` - MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas	Phase 1
Completed	`NCT00004241` - 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma	Phase 1
Recruiting	`NCT05377827` - Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies	Phase 1
Recruiting	`NCT04480788` - CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study	Phase 1
Completed	`NCT01254578` - Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers	Phase 1
Completed	`NCT01748721` - MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma	Phase 1
Completed	`NCT00901147` - Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma	Phase 2
Terminated	`NCT00101205` - Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma	Phase 1
Terminated	`NCT00096005` - Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas	Phase 1
Completed	`NCT00040846` - Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies	Phase 2